The U.S. Food and Drug Administration (FDA) issued a warning letter to Medline following an inspection that identified recurring bacterial contamination in the company’s finished drug products. The regulatory action addresses the manufacturer’s failure to implement adequate controls to prevent these contamination issues, which have persisted over a period of time.
FDA inspectors documented these findings during a recent review of the company’s manufacturing operations. The agency’s report specifies that Medline did not successfully mitigate the risks of bacterial presence in its pharmaceutical goods, despite previous oversight. This warning letter serves as a formal notification of the agency’s concerns regarding the company’s adherence to established safety and quality standards for drug production. Medline, which secured billions of dollars in funding last year, must now address these identified deficiencies to comply with federal manufacturing regulations.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: June 3, 2026
發佈留言